Terms: = Pancreatic cancer AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA AND Treatment
115 results:
1. Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan.
Cheng SM; Su YY; Chiang NJ; Wang CJ; Chao YJ; Huang CJ; Tsai HJ; Chen SH; Chang CY; Tsai CR; Li YJ; Yen CJ; Chuang SC; Chang JS; Shan YS; Hwang DY; Chen LT
J Biomed Sci; 2024 Feb; 31(1):21. PubMed ID: 38350919
[TBL] [Abstract] [Full Text] [Related]
2. Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy.
Cordero-Hernandez IS; Ross AC; Dasari A; Halperin DM; Chasen B; Yao JC
Endocr Relat Cancer; 2024 Apr; 31(4):. PubMed ID: 38329269
[TBL] [Abstract] [Full Text] [Related]
3. Inhibition of atm promotes PD-L1 expression by activating JNK/c-Jun/TNF-α signaling axis in triple-negative breast cancer.
Liu C; Qian X; Yu C; Xia X; Li J; Li Y; Xie Y; Gao G; Song Y; Zhang M; Xue H; Wang X; Sun H; Liu J; Deng W; Guo X
Cancer Lett; 2024 Apr; 586():216642. PubMed ID: 38278470
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment.
Ikezawa K; Urabe M; Kai Y; Takada R; Akita H; Nagata S; Ohkawa K
Jpn J Clin Oncol; 2024 Mar; 54(3):271-281. PubMed ID: 38109477
[TBL] [Abstract] [Full Text] [Related]
5. Cost-Effectiveness Analysis of Screening for pancreatic cancer Among High-Risk Populations.
Peters MLB; Eckel A; Seguin CL; Davidi B; Howard DH; Knudsen AB; Pandharipande PV
JCO Oncol Pract; 2024 Feb; 20(2):278-290. PubMed ID: 38086003
[TBL] [Abstract] [Full Text] [Related]
6. Clinical features of germline BRCA1/2 or atm pathogenic variant positive pancreatic cancer in Japan.
Kitamura H; Morizane C; Tanabe N; Go I; Maruki Y; Ohba A; Nagashio Y; Kondo S; Hijioka S; Ueno H; Yoshida T; Okusaka T
Pancreatology; 2023 Dec; 23(8):964-969. PubMed ID: 37914629
[TBL] [Abstract] [Full Text] [Related]
7. Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and atm, a Belgian Precision tumor-agnostic phase II study.
Joris S; Denys H; Collignon J; Rasschaert M; T'Kint de Roodenbeke D; Duhoux FP; Canon JL; Tejpar S; Mebis J; Decoster L; Aftimos P; De Grève J
ESMO Open; 2023 Dec; 8(6):102041. PubMed ID: 37852034
[TBL] [Abstract] [Full Text] [Related]
8. Reduced expression of phosphorylated ataxia-telangiectasia mutated gene is related to poor prognosis and gemcitabine chemoresistance in pancreatic cancer.
Xun J; Ohtsuka H; Hirose K; Douchi D; Nakayama S; Ishida M; Miura T; Ariake K; Mizuma M; Nakagawa K; Morikawa T; Furukawa T; Unno M
BMC Cancer; 2023 Sep; 23(1):835. PubMed ID: 37674118
[TBL] [Abstract] [Full Text] [Related]
9. STAT3 inhibition enhances gemcitabine sensitivity in pancreatic cancer by suppressing EMT, immune escape and inducing oxidative stress damage.
Guo H; Hu Z; Yang X; Yuan Z; Gao Y; Chen J; Xie L; Chen C; Guo Y; Bai Y
Int Immunopharmacol; 2023 Oct; 123():110709. PubMed ID: 37515849
[TBL] [Abstract] [Full Text] [Related]
10. Geographical, ethnic, and genetic differences in pancreatic cancer predisposition.
Liew SZH; Ng KW; Ishak NDB; Lee SY; Zhang Z; Chiang J; Ngeow JYY
Chin Clin Oncol; 2023 Jun; 12(3):27. PubMed ID: 37417291
[TBL] [Abstract] [Full Text] [Related]
11. pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis.
Zhao Z; Zhang W; Pang L; Zeng L; Liu S; Liu J
Front Immunol; 2023; 14():1166299. PubMed ID: 37359551
[TBL] [Abstract] [Full Text] [Related]
12. Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities.
Zhang L; Feng Q; Wang J; Tan Z; Li Q; Ge M
Biochim Biophys Acta Rev Cancer; 2023 Jul; 1878(4):188928. PubMed ID: 37257629
[TBL] [Abstract] [Full Text] [Related]
13. Molecular and Functional Heterogeneity of Primary pancreatic Neuroendocrine Tumors and Metastases.
Guo Y; Tian C; Cheng Z; Chen R; Li Y; Su F; Shi Y; Tan H
Neuroendocrinology; 2023; 113(9):943-956. PubMed ID: 37232011
[TBL] [Abstract] [Full Text] [Related]
14. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis.
Zhou T; Xie Y; Hou X; Bai W; Li X; Liu Z; Man Q; Sun J; Fu D; Yan J; Zhang Z; Wang Y; Wang H; Jiang W; Gao S; Zhao T; Chang A; Wang X; Sun H; Zhang X; Yang S; Huang C; Hao J; Liu J
J Exp Clin Cancer Res; 2023 May; 42(1):111. PubMed ID: 37143164
[TBL] [Abstract] [Full Text] [Related]
15. Analysis of Plasma Circulating Tumor DNA in Borderline Resectable pancreatic cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Damage Repair Gene Alteration Detection.
Lim DH; Yoon H; Kim KP; Ryoo BY; Lee SS; Park DH; Song TJ; Hwang DW; Lee JH; Song KB; Kim SC; Hong SM; Hyung J; Yoo C
Cancer Res Treat; 2023 Oct; 55(4):1313-1320. PubMed ID: 37139665
[TBL] [Abstract] [Full Text] [Related]
16. Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan.
Sakakida T; Ishikawa T; Doi T; Morita R; Kataoka S; Miyake H; Yamaguchi K; Moriguchi M; Sogame Y; Yasuda H; Iwasaku M; Konishi H; Takayama K; Itoh Y
J Gastroenterol; 2023 Jun; 58(6):575-585. PubMed ID: 37029223
[TBL] [Abstract] [Full Text] [Related]
17. Prevalence and Risk Factors of Germline Pathogenic Variants in pancreatic Ductal Adenocarcinoma.
Ryu KH; Park S; Chun JW; Cho E; Choi J; Lee DE; Shim H; Kim YH; Han SS; Park SJ; Woo SM; Kong SY
Cancer Res Treat; 2023 Oct; 55(4):1303-1312. PubMed ID: 37024097
[TBL] [Abstract] [Full Text] [Related]
18. Adherence to NCCN Genetic Testing Guidelines in pancreatic cancer and Impact on Treatment.
Crowley F; Gandhi S; Rudshteyn M; Sehmbhi M; Cohen DJ
Oncologist; 2023 Jun; 28(6):486-493. PubMed ID: 36933202
[TBL] [Abstract] [Full Text] [Related]
19. Transanal endoscopic microsurgery versus radical resection for early-stage rectal cancer: a systematic review and meta- analysis.
Li W; Xiang XX; Da Wang H; Cai CJ; Cao YH; Liu T
Int J Colorectal Dis; 2023 Feb; 38(1):49. PubMed ID: 36800079
[TBL] [Abstract] [Full Text] [Related]
20. Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours.
Huang MTF; Sharma V; Mendelsohn A; Wei Q; Li J; Yu B; Larrick JW; Lum LG
Ann Med; 2022 Dec; 54(1):1047-1057. PubMed ID: 36799362
[No Abstract] [Full Text] [Related]
[Next]